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The clinical use of implantable cardioverter
defibrillators (ICDs) has increased rapidly since the
results of several randomized trials confirmed the
efficacy of ICDs in the secondary and primary pre-
vention of sudden cardiac death [1].
The more complex devices are leading to a ra-
pidly increasing workload for the follow-up of the-
se patients in specialized centres. According to in-
ternational guidelines, ICD patients should be fol-
lowed at intervals of between one and four months,
depending on the ICD model and clinical status [2].
Increasing numbers of follow-ups for ICD pa-
tients are among the main problems for healthcare
systems worldwide.
Recent advances in wireless communication,
data storage and implantable electronic technolo-
gies have ushered in a new era of real-time, remote
electrocardiographic monitoring using implantable
devices [3].
Many studies have shown the ability of remo-
te monitoring to reduce follow-up in patients with
ICD, to detect serious ICD defects and to check on
a patient’s daily clinical condition [4–7].
One of the first remote follow-up options for
patients with an ICD is Home Monitoring by Bio-
tronik, a revolutionary system that allows a defibril-
lator to connect to the cellphone network in such
a way that it can communicate directly with the phy-
sician.
Home Monitoring works with a small device
called the CardioMessenger (CM), about the size
of a large cellphone. CM communicates via the
world cellphone network (GPRS network). The ICD
contains a built-in antenna that periodically dispat-
ches reports on the patient’s heart and the functio-
ning of the device. The CM picks up these signals
and forwards them to a service center, which pro-
cesses the information and posts it on a secure web-
site for review by the doctor. Urgent matters can
go directly to physicians by fax, email, SMS and te-
lephone. The physician can review the Home Moni-
toring reports and if anything is wrong, he or she will
call the patient to make an appointment (Fig. 1).
Biotronik’s Home Monitoring system is at the
moment the only one which can act completely au-
tomatically. Unlike all other telemonitoring sys-
tems, all information from the patient’s device to
the doctor is sent without the patient having to do
anything.
Home Monitoring keeps the doctor informed
as to what is going on with the heart and the im-
planted device. The objective is to make data avail-
able for:
— diagnosis of the arrhythmia with internal
electrogram (IEGM) available on line;
— monitoring of the patient’s status;
— analysis of the effectiveness of therapies
delivered by the implant;
Figure 1. Biotronik Home Monitoring for follow-up patients with implantable cardioverter-defibrillators.
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— monitoring of the technical status of the
implant and the leads.
The other unique feature of Home Monitoring
is its capacity for atrial fibrillation and heart failure
monitoring. The physician can get crucial informa-
tion about patients with ICD-CRT, for example the
percentage of resynchronization therapy, the left
ventricular pacing threshold or the thoracic fluid
status (though at present this can only be done via
a special code). All those factors mean that doctors
can predict an  increase of heart failure symptoms
and call patients in for earlier follow-up. Such com-
plex monitoring of heart failure patients is a great
innovation in telemedicine technology (Fig. 2).
Another new concept being introduced by
Home Monitoring is the possibility of ‘bidirectio-
nal’ communication: i.e. from the patient’s device
to CM to the physician (Fig. 3).
In the latest CardioMessenger II, anything
wrong is detected by the system, reviewed by the
physician on a screen and a ‘callback’ function is
available. The doctor can send information to the
patient’s CM with a yellow flashing link, indicating
that he should call the cardiologist.
Last but not least, Biotronik is introducing
a new website platform for Home Monitoring which
Figure 2. Heart failure parameters monitored by Home
Monitoring.
Figure 4. Patient’s color status with the new Home Monitoring platform.
Figure 3. CardioMessenger II with bidirectional connection.
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facilitates the follow-up. The physician can see a list
of patients for review. If anything important has
occurred in a particular patient, he or she will be
classified as ‘red’. In this way, a doctor, upon log-
ging onto the website, can immediately see if there
are patients who need attention. The color code
helps differentiate clinical priorities (Fig. 4).
The launch of Home Monitoring is an important
milestone in the management of ICD patients. It brings
a high level of convenience for patients and clinicians
and facilitates the follow-up of those patients.
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